Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2– metastatic breast cancer in the United States

References

• American Cancer Society. Cancer facts & figures 2019. 2019 [cited 2019 Sept 4]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013 Aug;274(2):113–126.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–29.
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI. 2014 May 1;106(5). DOI:10.1093/jnci/dju055.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer. Version 1. 2016 [cited 2016 Feb]. Available from: http://www.nccn.org‌/professionals‌/physician_gls‌/f_guidelines.asp
   Google Scholar
• Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014;25:1871–1888.
   PubMed Web of Science ®Google Scholar
• Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. 2015;7:304–320.
   PubMed Web of Science ®Google Scholar
• Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771–1785.
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Guerin A, Brammer M, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist. 2014 Sept;19(9):901–908.
   PubMed Web of Science ®Google Scholar
• Ray S, Bonthapally V, McMorrow D, et al. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population. J Comp Eff Res. 2013;2:195–206.
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Weycker D, Glass A, et al. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer. 2011;11:250.
   PubMed Web of Science ®Google Scholar
• Donato BM, Burns L, Willey V, et al. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report. Clin Ther. 2010;32:546–554.
   PubMed Web of Science ®Google Scholar
• Force RW, Pugmire BA, Culbertson VL. Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis. Am Health Drug Benefits. 2010 July;3(4):276.
   PubMedGoogle Scholar
• Wan Y, Gao X, Mehta S, et al. Indirect costs associated with metastatic breast cancer. J Med Econ. 2013 Oct;16(10):1169–1178.
   PubMedGoogle Scholar
• Li N, Hao Y, Koo V, et al. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. J Med Econ. 2016;19(4):414–423.
   PubMed Web of Science ®Google Scholar
• Hao Y, Meyer N, Song X, et al. Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics. Curr Med Res Opin. 2015;31:275–288.
   PubMed Web of Science ®Google Scholar
• Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin. 2014;30:1537–1545.
   PubMed Web of Science ®Google Scholar
• Meadows ES, Johnston SS, Cao Z, et al. Illness-associated productivity costs among women with employer-sponsored insurance and newly diagnosed breast cancer. J Occup Environ Med. 2010 Apr;52(4):415–420.
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Kartashov A, et al. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy. 2012;58:8–18.
   PubMed Web of Science ®Google Scholar
• Allen LA, Smoyer Tomic KE, Smith DM, et al. Rates and predictors of 30-day readmission among commercially insured and medicaid-enrolled patients hospitalized with systolic heart failure. Circ Heart Fail. 2012;5:672–679.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61:1234–1240.
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584–590.
   PubMed Web of Science ®Google Scholar
• Goyal RK, Wheeler SB, Kohler RE, et al. Health care utilization from chemotherapy-related adverse events among low-income breast cancer patients. N C Med J. 2014;75:231–238.
   PubMedGoogle Scholar
• Wheeler SB, Kohler RE, Goyal RK, et al. Is medical home enrollment associated with receipt of guideline-concordant follow-up care among low-income breast cancer survivors? Med Care. 2013;51:494–502.
   PubMed Web of Science ®Google Scholar
• Mack CD, Carpenter W, Meyer AM, et al. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. Cancer. 2012;118:2925–2934.
   PubMed Web of Science ®Google Scholar
• Strauss JB, Gielda BT, Chen SS, et al. Variation in post-surgical lumpectomy cavity volume with delay in initiation of breast irradiation because of chemotherapy. Int J Radiat Oncol Biol Phys. 2010;77:831–835.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Hackshaw MD, Oster G. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma. J Med Econ. 2013;16:1300–1306.
   PubMedGoogle Scholar
• Hassett MJ, O’Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98:1108–1117.
   PubMed Web of Science ®Google Scholar
• United States Bureau of Labor Statistics. Usual weekly earnings of wage and salary workers, third quarter 2016. 2016 Oct 20 [cited 2017 Aug 8]. Available from: https://www.bls.gov/news.release/archives/wkyeng_10202016.pdf
   Google Scholar
• Karve S, Misurski DA, Meier G, et al. Employer-incurred health care costs and productivity losses associated with influenza. Hum Vaccin Immunother. 2013;9:841–857.
   PubMed Web of Science ®Google Scholar
• Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016 Feb;9(1):23–32.
   PubMed Web of Science ®Google Scholar
• Montero AJ, Eapen S, Gorin B, et al. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat. 2012 July;134(2):815–822.
   PubMed Web of Science ®Google Scholar
• Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004 Jan;83(1):25–32.
   PubMed Web of Science ®Google Scholar
• Meyer N, Hao Y, Song X, et al. Healthcare resource use and expenditures among metastatic breast cancer patients treated with HER2-targeted agents. Int J Breast Cancer. 2014;2014:475171.
   PubMedGoogle Scholar
• Davis KL, Iyer S, Candrilli S. Predictors of the direct costs of breast cancer in the United States elderly population. Value Health. 2010 Nov 1;13(7):A260.
   Web of Science ®Google Scholar
• Goyal RK, Carter GC, Nagar SP, et al. Treatment patterns, survival and economic outcomes in medicare-enrolled, older patients with HR+/HER2− metastatic breast cancer. Curr Med Res Opin. 2019 Oct 3;35(10):1699–1710.
   PubMed Web of Science ®Google Scholar
• Dickman SL, Himmelstein DU, Woolhandler S. Inequality and the health-care system in the USA. Lancet. 2017 Apr 8;389(10077):1431–1441.
   PubMed Web of Science ®Google Scholar
• Lidgren M, Wilking N, Jonsson B, et al. Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care. 2007;23:223–231.
   PubMed Web of Science ®Google Scholar